PT  - JOURNAL ARTICLE
AU  - Blair, Paul W.
AU  - Brandsma, Joost
AU  - Chenoweth, Josh
AU  - Richard, Stephanie A.
AU  - Epsi, Nusrat J.
AU  - Mehta, Rittal
AU  - Striegel, Deborah
AU  - Clemens, Emily G.
AU  - Lindholm, David A.
AU  - Maves, Ryan C.
AU  - Larson, Derek T.
AU  - Mende, Katrin
AU  - Colombo, Rhonda E.
AU  - Ganesan, Anuradha
AU  - Lalani, Tahaniyat
AU  - Colombo, Christopher J
AU  - Malloy, Allison A.
AU  - Snow, Andrew L.
AU  - Schully, Kevin L.
AU  - Lanteri, Charlotte
AU  - Simons, Mark P.
AU  - Dumler, John S.
AU  - Tribble, David
AU  - Burgess, Timothy
AU  - Pollett, Simon
AU  - Agan, Brian K.
AU  - Clark, Danielle V.
AU  - ,
TI  - Topological data analysis identifies distinct biomarker phenotypes during the ‘inflammatory’ phase of COVID-19
AID  - 10.1101/2021.12.25.21268206
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.12.25.21268206
4099  - http://medrxiv.org/content/early/2021/12/29/2021.12.25.21268206.short
4100  - http://medrxiv.org/content/early/2021/12/29/2021.12.25.21268206.full
AB  - OBJECTIVES The relationships between baseline clinical phenotypes and the cytokine milieu of the peak ‘inflammatory’ phase of coronavirus 2019 (COVID-19) are not yet well understood. We used Topological Data Analysis (TDA), a dimensionality reduction technique to identify patterns of inflammation associated with COVID-19 severity and clinical characteristics.DESIGN Exploratory analysis from a multi-center prospective cohort study.SETTING Eight military hospitals across the United States between April 2020 and January 2021.PATIENTS Adult (≥18 years of age) SARS-CoV-2 positive inpatient and outpatient participants were enrolled with plasma samples selected from the putative ‘inflammatory’ phase of COVID-19, defined as 15-28 days post symptom onset.INTERVENTIONS None.MEASUREMENTS AND MAIN RESULTS Concentrations of 12 inflammatory protein biomarkers were measured using a broad dynamic range immunoassay. TDA identified 3 distinct inflammatory protein expression clusters. Peak severity (outpatient, hospitalized, ICU admission or death), Charlson Comorbidity Index (CCI), and body mass index (BMI) were evaluated with logistic regression for associations with each cluster. The study population (n=129, 33.3% female, median 41.3 years of age) included 77 outpatient, 31 inpatient, 16 ICU-level, and 5 fatal cases. Three distinct clusters were found that differed by peak disease severity (p <0.001), age (p <0.001), BMI (p<0.001), and CCI (p=0.001).CONCLUSIONS Exploratory clustering methods can stratify heterogeneous patient populations and identify distinct inflammation patterns associated with comorbid disease, obesity, and severe illness due to COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project has been funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, under Inter-Agency Agreement Y1-AI-5072, the Defense Health Program, U.S. DoD, under award HU0001190002, and the Defense Health Agency, U.S. DoD, under awards HU00012020070 and W911QY-20-9-0006. Biomarker assay reagents and analysis support was provided by JPEO W911QY-20-9-0004 (2020 OTA).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol was approved by the Uniformed Services University Institutional Review Board (IRB# IDCRP-085)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors